<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211298</url>
  </required_header>
  <id_info>
    <org_study_id>0312-19-RMC</org_study_id>
    <nct_id>NCT04211298</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Propofol Sedation in Flexible Bronchoscopy: A Randomized Controlled Trial</brief_title>
  <official_title>Dexmedetomidine Versus Propofol Sedation in Flexible Bronchoscopy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate clinical outcomes during bronchoscopy procedures with dexmedetomidine
      in comparison to propofol.

      The clinical outcomes that will be evaluated are: oxygen saturation, transcutaneous Pco2,
      blood pressure and complications
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of de-saturation events</measure>
    <time_frame>During the procedure</time_frame>
    <description>Number of events during bronchoscopy when saturation level decreased under 90%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation time &lt; 90%</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total time during the procedure that the oxygen saturation was under 90%</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sedation Complication</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine will be used for sedation during bronchoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Propofol will be used for sedation during bronchoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine will be used for sedation during bronchoscopy</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in the age group 18 to 70 years requiring flexible bronchoscopic
             evaluation of the airway in the Pulmonary institute at Rabin medical center

        Exclusion Criteria:

          -  known or suspected allergy to any of the study drugs, seizure disorder, renal (with
             serum creatinine &gt; 2 mg/dL) or hepatic impairment (elevated liver enzymes &gt; 2 times
             normal), haemodynamic instability (bradycardia with HR &lt; 50 bpm or hypotension with
             SBP &lt; 90 mmHg), or seriously ill patients with American Society of Anesthesiologists'
             physical status above III
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barak Pertzov, MD</last_name>
    <phone>972548080196</phone>
    <email>pertzovb@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mordechai Kramer, MD</last_name>
    <phone>97239377224</phone>
    <email>Kremerm@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mordechai R Kramer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mordechai R Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Mordechai Kremer</investigator_full_name>
    <investigator_title>Head of the pulmonary division</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

